Publications by authors named "Qidi Ying"

Claim this Profile
B
Between Scylla and Charybdis - Enigmatic role of lipoprotein(a) in atherosclerotic cardiovascular disease and type 2 diabetes mellitus.
Qing Li, Jing Xu, Zi Xiong, Qidi Ying

Diabetes Res Clin Pract· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved arterial inflammation with high dose omega-3 fatty acids in patients with elevated lipoprotein(a): Selective effect of eicosapentaenoic acid?
Natalie C Ward, Qidi Ying, Dick C Chan, Jing Pang, Trevor A Mori

J Clin Lipidol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does fish oil supplementation increase cholesterol efflux capacity in familial hypercholesterolaemia?
Dick C Chan, Annalisa Ronca, Qidi Ying, Jing Pang, Mikaël Croyal

Eur J Clin Invest· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of omega-3 fatty acid ethyl esters on postprandial arterial elasticity in patients with familial hypercholesterolemia.
Qidi Ying, Dick C Chan, Jing Pang, Mikaël Croyal, Valentin Blanchard

Clin Nutr ESPEN· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia.
Qidi Ying, Mikaël Croyal, Dick C Chan, Valentin Blanchard, Jing Pang

J Atheroscler Thromb· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol-lowering treatments?
Qidi Ying, Annalisa Ronca, Dick C Chan, Jing Pang, Elda Favari

Eur J Clin Invest· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin-treated patients with very high apolipoprotein(a) concentration.
Qidi Ying, Dick C Chan, Jing Pang, Santica M Marcovina, Peter Hugh R Barrett

J Intern Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies.
Dick C Chan, Qidi Ying, Gerald F Watts

Curr Opin Lipidol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unravelling lipoprotein metabolism with stable isotopes: tracing the flow.
Qidi Ying, Dick C Chan, P Hugh R Barrett, Gerald F Watts

Metabolism· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiopoietin-like protein 3 inhibitors and contemporary unmet needs in lipid management.
Qidi Ying, Dick C Chan, Gerald F Watts

Curr Opin Lipidol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects.
Qidi Ying, Dick C Chan, Gerald F Watts

Front Physiol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
Gerald F Watts, Dick C Chan, Jing Pang, Louis Ma, Qidi Ying

Metabolism· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decrease of AIM2 mediated by luteolin contributes to non-small cell lung cancer treatment.
Qian Yu, Minda Zhang, Qidi Ying, Xin Xie, Shuwen Yue

Cell Death Dis· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: an update.
Qidi Ying, Guanzhong Wu

Ren Fail· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
G004, a synthetic sulfonylurea compound, exerts anti-atherosclerosis effects by targeting SIRT1 in ApoE mice.
Lifen Qian, Lingman Ma, Guanzhong Wu, Qian Yu, Huisheng Lin, Qidi Ying

Vascul Pharmacol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
I, a synthetic anti-diabetes agent, attenuates atherosclerosis through its lipid-lowering, anti-inflammatory and anti-apoptosis properties.
Lingman Ma, Lifen Qian, Qidi Ying, Yan Zhang, Changlin Zhou

Mol Cell Endocrinol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis